Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Macy's (M) downgraded to Neutral from Buy at Buckingham with the firm lowering its price target to $30 from $39 to reflect the lack of visibility on its ability to re-accelerate comparative sales, overwhelming pressure from online and off-price competition, and its inability to continue to reduce expenses sufficiently to offset EBITDA declines over the next few years. 2. Fitbit (FIT) downgraded to Sell from Neutral at Citi with analyst Stanley Kovler citing the company's negative preliminary fourth quarter announcement and 2017 outlook that came in "significantly below" expectations. Market saturation is having a real effect on the company's results, and management "demonstrated a clear lack of visibility" into its distribution network, Kovler tells investors in a research note. The analyst cut his price target for the shares to $5 from $8. 3. Under Armour (UA, UAA) downgraded to Underperform from Market Perform at Raymond James, to Neutral from Positive at Susquehanna, and to Neutral from Overweight at Piper Jaffray. 4. Ixia (XXIA) was downgraded to Neutral from Buy at DA Davidson and to Hold from Buy at Gabelli. 5. Ocera Therapeutics (OCRX) downgraded to Market Perform at JMP Securities with analyst Liisa Bayko citing Phase 2 data which showed that the company's hepatic encephalopathy treatment missed its primary endpoint. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.